RxSight Q1 net loss widens to $(15.9) million; sales fall 18.5% to $30.9 million

• RxSight posted Q1 sales of $30.9 million, down 18.5% year over year, driven by 27,472 Light Adjustable Lens units.
• Net loss widened to $15.9 million, or $0.38 per share, from a loss of $8.2 million, or $0.20 per share.
• Gross margin rose to 76.1% from 74.8%, due to a favorable shift in product mix toward Light Adjustable Lens sales.
• Light Delivery Device sales totaled 20, lifting installed base to 1,154; cash, cash equivalents and short-term investments were $217.9 million.
• Full-year outlook was reiterated for revenue of $120 million to $135 million and gross margin of 70% to 72%, with operating expenses expected at high end of $150 million to $160 million range.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RxSight Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-208912), on May 06, 2026, and is solely responsible for the information contained therein.